Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Topical spironolactone is discussed as a potential treatment for androgenic alopecia, with the user seeking feedback on its effectiveness. Minoxidil, finasteride, and other treatments like microneedling and keto shampoo are mentioned as alternatives.

Melatonin is being considered as a potential treatment for androgenic alopecia, with some users discussing its effects and combining it with other treatments like minoxidil and finasteride. Concerns about melatonin's impact on hormones and side effects from other treatments like ketoconazole were also discussed.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

Soy consumption may help prevent androgenic alopecia, but it can decrease sexual drive in some men. There is a connection between soy and androgenic alopecia, suggesting a potential protective effect.

Cetirizine 1% cream significantly improves hair growth and thickness in men with androgenic alopecia. It is considered effective, affordable, and has a low side effect profile.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

Hair loss discussion involves spironolactone and bicalutamide for women's androgenic alopecia. Focus on effectiveness and side effects.

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

2-deoxy-D-ribose, a sugar molecule, is found to be 80%-90% as effective as Minoxidil in promoting hair growth, showing potential for alopecia treatment. Concerns include high cost, lack of human studies, and possible side effects like diarrhea and nausea.

Topical formulations, natural products, and CAM therapies are being used to treat Androgenic alopecia to avoid side effects of Finasteride and Minoxidil. The review covers various low-risk, alternative treatment options.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

A user with aggressive androgenic alopecia is considering increasing their dutasteride dose from 0.5 mg to potentially 2.5 mg, while already using oral minoxidil, Nizoral, RU-58841, and dermapen. They are seeking advice on the effectiveness and side effects of higher dutasteride doses, with suggestions to consult a dermatologist and consider a higher Nizoral concentration.

A user with androgenic alopecia seeks advice on making topical spironolactone from pills due to poor reactions to the oral form and its unavailability in their country. They are looking for guidance on preparing it themselves.

A user experienced facial swelling while taking spironolactone for androgenic alopecia, despite its diuretic properties. They are unsure about increasing the dose due to this side effect.

The dermatologist diagnosed androgenic alopecia and prescribed minoxidil and a shampoo for dandruff, avoiding finasteride due to side effects. The user questions the dermatologist's approach and considers seeking a second opinion due to concerns about the lack of a physical scalp check initially.

A woman with androgenic alopecia has been using birth control, spironolactone, finasteride, and oral minoxidil for hair loss. She sought to change her medications to dutasteride and bicalutamide, but her new dermatologist refused to prescribe them for off-label use.

A user is experiencing androgenic alopecia and is considering using Vichy's aminexil for hair regrowth. They seek advice on its effectiveness and whether to combine it with microneedling.

Potential cures for Androgenic Alopecia, specifically Kintor/HMI 115, CosmeRNA, Minoxidil and Finasteride.

27F with androgenic alopecia since 17 seeks treatment. Tried spironolactone, caused low blood pressure; believes finasteride is safer and wants to try it.

A 30-year-old male with androgenic alopecia started using topical Minoxidil in 2018, Finasteride in 2020, and switched to oral Minoxidil and Dutasteride after Finasteride stopped working. He underwent hair transplants in 2022 and 2025, showing significant improvement in recent photos.

A 30-year-old male with androgenic alopecia shows progress after using dutasteride (0.5 mg daily) and topical minoxidil (5% twice daily) for 3.5 months. Users suggest adding dermastamping for better results.

A 25-year-old woman with androgenic alopecia is experiencing hair dryness and damage after using topical minoxidil and Nizoral. She is advised to reduce washing frequency, use a bond builder like K18, apply a silicone-based serum, and consider using a shower filter and different oils like argan oil for better hair health.

A 29-year-old male with androgenic alopecia was treated with oral Dutasteride, oral Minoxidil, and injectable Dutasteride, showing progress in 9 months. Some users believe Dutasteride mesotherapy is unnecessary and question its effectiveness compared to topical applications.

A 25-year-old woman with androgenic alopecia has been using minoxidil, spironolactone, and dutasteride but sees little improvement in hair thinning. She is considering switching to oral minoxidil and exploring other treatments like PRP and hair systems.

A user is asking women with androgenic alopecia about the effective dose of spironolactone for hair regrowth, mentioning they've been on 100 mg for a year with minimal results and considering increasing the dose. The conversation focuses on the effectiveness of spironolactone for hair loss treatment.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.